Описание
Clinical evidence for Saccharomyces boulardii CNCM I-745 in preventing antibiotic-associated diarrhea, summarizing key randomized controlled trials. Pooled data suggest a significant reduction in diarrhea incidence when the probiotic yeast is co-administered with antibiotics.
Figure 3
ChartSource Paper
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.Cite This Figure
![Figure 3: Clinical evidence for Saccharomyces boulardii CNCM I-745 in preventing antibiotic-associated diarrhea, summarizing key randomized controlled trials. Pooled data suggest a significant reduction in diarrhea incidence when the probiotic yeast is co-administered with antibiotics.]() > Source: Sarath Gopalan et al. "Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narra." *Cureus*, 2023. PMID: [37927652](https://pubmed.ncbi.nlm.nih.gov/37927652/)
<figure> <img src="" alt="Clinical evidence for Saccharomyces boulardii CNCM I-745 in preventing antibiotic-associated diarrhea, summarizing key randomized controlled trials. Pooled data suggest a significant reduction in diarrhea incidence when the probiotic yeast is co-administered with antibiotics." /> <figcaption>Figure 3. Clinical evidence for Saccharomyces boulardii CNCM I-745 in preventing antibiotic-associated diarrhea, summarizing key randomized controlled trials. Pooled data suggest a significant reduction in diarrhea incidence when the probiotic yeast is co-administered with antibiotics.<br> Source: Sarath Gopalan et al. "Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narra." <em>Cureus</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37927652/">37927652</a></figcaption> </figure>